FDA Lifts Ban on Juul E-Cigarettes

FDA Approves Juul E-Cigarettes for Adult Use, Reversing Previous Ban

The U.S. Food and Drug Administration (FDA) has approved the continued sale of Juul Labs’ e-cigarettes, marking a significant shift in the agency’s stance on the popular vaping brand. This decision comes after the agency previously banned the company’s products in 2022, citing concerns over their impact on youth and public health.

The FDA announced on Thursday that it will allow the sale of Juul’s original e-cigarette device along with refill cartridges in tobacco and menthol flavors. The approval is based on an extensive scientific review that concluded the benefits for adult smokers outweigh the risks to non-smokers or young people. According to the agency, Juul provided evidence showing high rates of adults transitioning from traditional cigarettes to its tobacco- or menthol-flavored products.

While the FDA’s decision permits these specific e-cigarette products to be legally marketed to adults aged 21 and older, it explicitly states that the products are not safe or FDA-approved. The agency emphasized that this authorization does not imply any endorsement of the products as being harmless or suitable for all users.

Juul once dominated the vaping market, becoming synonymous with the industry itself. However, as more young people began using its fruit and candy-flavored products, the company faced increasing scrutiny. Juul has consistently denied allegations that it targeted children and teens in its marketing efforts.

In 2022, the FDA announced a nationwide ban on Juul e-cigarettes, claiming the company had not demonstrated that keeping its products on the market would be appropriate for public health. Shortly after, the agency suspended the order to conduct an internal review of the scientific data submitted by Juul.

Despite the pause, the FDA’s actions nearly led to the company’s bankruptcy. Juul later paid $1.7 billion to resolve thousands of lawsuits alleging that it aggressively marketed its products to young people, contributing to a vaping crisis. The FDA considered Juul’s appeal for two years before formally rescinding the ban in 2024, restarting the scientific review process for the company’s application.

All electronic cigarette products must receive FDA authorization to be legally sold in the United States. Companies are required to submit scientific evidence demonstrating that their products offer public health benefits.

K.C. Crosthwaite, CEO of Juul Labs, stated in a release: “Today’s FDA authorization of JUUL products marks an important step toward making the cigarette obsolete.” He added that the company strongly supports the FDA’s role in regulating tobacco and nicotine products, emphasizing the importance of offering high-quality, innovative, and responsibly marketed alternatives for adult nicotine users.

However, Juul no longer holds the dominant position it once had in the market. The company has lost significant market share due to increased competition, including from e-cigarettes illegally imported from China.

Anti-tobacco groups have expressed disappointment with the FDA’s decision, warning that it could reverse recent progress in reducing youth e-cigarette use. Yolonda Richardson, president and CEO of the Campaign for Tobacco-Free Kids, criticized the move, stating: “It is a big step in the wrong direction to authorize sales of the product that was responsible for this public health crisis in the first place.”

Ranjana Caple, senior manager of federal advocacy for the American Lung Association, echoed similar concerns, calling the decision a “serious misstep.” She pointed to Juul’s role in the rise of youth vaping, noting that the company’s sleek devices and enticing flavors contributed to a generation of young people becoming addicted to nicotine.

The FDA’s decision highlights the complex balance between supporting adult smokers seeking alternatives to traditional cigarettes and preventing youth access to nicotine products. As the debate continues, the agency’s approval of Juul’s products signals a new chapter in the ongoing conversation about e-cigarettes and public health.